Nanology Labs is a Canadian biotechnology company developing novel cancer therapies using our novel drug-delivery platform nanotechnology (TERP). It offers flexible payload capacity (e. g. drugs, siRNA, antibodies, and proteins), favorable drug release and pharmacokinetics, antibody-guided targeting, and tunable brain penetration. Our lead asset (T-MX) is a theranostic product that combines tumor detection and ablation in a single agent. It is poised to enter the clinic in 2022, with the potential to become a breakthrough neoadjuvant with first-in-line therapies in the large market of cold, oxygen-starved, treatment-resistant, solid tumor cancers.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):